Cargando…

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

[Image: see text] A data-centric medicinal chemistry approach led to the invention of a potent and selective IDO1 inhibitor 4f, INCB24360 (epacadostat). The molecular structure of INCB24360 contains several previously unknown or underutilized functional groups in drug substances, including a hydroxy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yue, Eddy W., Sparks, Richard, Polam, Padmaja, Modi, Dilip, Douty, Brent, Wayland, Brian, Glass, Brian, Takvorian, Amy, Glenn, Joseph, Zhu, Wenyu, Bower, Michael, Liu, Xiangdong, Leffet, Lynn, Wang, Qian, Bowman, Kevin J., Hansbury, Michael J., Wei, Min, Li, Yanlong, Wynn, Richard, Burn, Timothy C., Koblish, Holly K., Fridman, Jordan S., Emm, Tom, Scherle, Peggy A., Metcalf, Brian, Combs, Andrew P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2017
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430407/ https://www.ncbi.nlm.nih.gov/pubmed/28523098 http://dx.doi.org/10.1021/acsmedchemlett.6b00391

Ejemplares similares

IDO-1 inhibitor INCB24360 elicits distant metastasis of basal extruded cancer cells in pancreatic ductal adenocarcinoma
por: Buhe, Hada, et al.
Publicado: (2022)

Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
por: Komiya, Takefumi, et al.
Publicado: (2018)

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
por: Liu, Phillip C. C., et al.
Publicado: (2020)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
por: Panfili, Eleonora, et al.
Publicado: (2023)

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
por: Gangadhar, Tara C, et al.
Publicado: (2015)

Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
por: Koblish, Holly K., et al.
Publicado: (2022)

Pharmacological inactivation of PI3Kδ in the tumor microenvironment enhances efficacy of other immunotherapeutic agents
por: Wang, Liang-Chuan S, et al.
Publicado: (2015)

Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies
por: Koblish, Holly, et al.
Publicado: (2018)

Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy
por: Wang, Zhiren, et al.
Publicado: (2023)

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL
por: Jochems, Caroline, et al.
Publicado: (2015)

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
por: Jochems, Caroline, et al.
Publicado: (2016)

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2014)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
por: Cao, Tingming, et al.
Publicado: (2022)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

Special instruction for the Engineer in Charge: Long Bubble Chamber run (21.3 to 24.3.60)
por: Brianti, G, et al.
Publicado: (1960)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis
por: Mancuso, Roberta, et al.
Publicado: (2015)

Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma
por: Loeser, Heike, et al.
Publicado: (2020)

Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
por: Arinola, Ganiyu Olatunbosun, et al.
Publicado: (2023)

Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus
por: Reinhart, Bonnie, et al.
Publicado: (2012)

Indoleamine 2,3-Dioxygenase (IDO) Downregulates the Cell Surface Expression of the CD4 Molecule
por: Huang, Guanyou, et al.
Publicado: (2012)

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
por: Tang, Kai, et al.
Publicado: (2021)

Indoleamine 2,3 dioxygenase (IDO) level as a marker for significant coronary artery disease
por: Wongpraparut, Nattawut, et al.
Publicado: (2021)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG(35-55)-induced experimental autoimmune encephalomyelitis
por: Wetzel, Lisa A., et al.
Publicado: (2020)

Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
por: Röhrig, Ute F., et al.
Publicado: (2022)

Indoleamine 2,3‐dioxygenase 1 (IDO1): an up‐to‐date overview of an eclectic immunoregulatory enzyme
por: Pallotta, Maria Teresa, et al.
Publicado: (2021)

Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
por: Yang, Pengbo, et al.
Publicado: (2023)

Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine
por: Tahaghoghi-Hajghorbani, Sahar, et al.
Publicado: (2023)

Respiratory syncytial virus replication induces Indoleamine 2,3-dioxygenase (IDO) activation in human dendritic cells
por: Ajamian, Farnam, et al.
Publicado: (2010)

Indoleamine 2,3-dioxygenase (IDO) is expressed at feto-placental unit throughout mouse gestation: An immunohistochemical study
por: Hemmati, Shayda, et al.
Publicado: (2009)

Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
por: Bonanno, Giuseppina, et al.
Publicado: (2012)

Preclinical assessment of a novel small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1)
por: Driessens, Gregory, et al.
Publicado: (2014)

Indoleamine 2,3-Dioxygenase 1 (Ido1) Is Involved in the Control of Mouse Caput Epididymis Immune Environment
por: Jrad-Lamine, Aicha, et al.
Publicado: (2013)

Mathematical modelling of the synergistic combination of radiotherapy and indoleamine-2,3-dioxygenase (IDO) inhibitory immunotherapy against glioblastoma
por: Chakwizira, Arthur, et al.
Publicado: (2018)

Immunohistochemical Features of Indoleamine 2,3-Dioxygenase (IDO) in Various Types of Lymphoma: A Single Center Experience
por: Kim, Mee-seon, et al.
Publicado: (2020)

Human Indoleamine 2,3-dioxygenase 1 (IDO1) Expressed in Plant Cells Induces Kynurenine Production
por: Bellucci, Michele, et al.
Publicado: (2021)

Fatigue in Patients on Chronic Hemodialysis: The Role of Indoleamine 2,3-Dioxygenase (IDO) Activity, Interleukin-6, and Muscularity
por: Molfino, Alessio, et al.
Publicado: (2023)

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_prqljnfiog7fnmqvsfjismvv9c